Health-Care Overhaul and Industry Outlook: Baxter

Published On: April 24th, 2010

Baxter cut its 2010 earnings estimate by 28 cents, 10 cents of which it attributed to Medicaid drug rebates.

See original here:
Health-Care Overhaul and Industry Outlook: Baxter

STOP PANIC ATTACKS - A Natural Technique To Stop Panic Attacks and Anxiety Fast!

The technique I teach has been developed by me Joe Barry, a former sufferer of all too frequent panic attacks and GAD. I developed a completely natural approach to eliminating 100% of general anxiety and panic attacks. This may seem very hard to believe for someone who may have had this condition for some time but believe me the new information is now available to be free from anxiety. I will reveal the whole technique to you.

Did you know:

Cancer is the leading cause of death for Asians and Pacific Islanders, and it is the second leading cause of death among every other racial and ethnic minority group in the United States

frkofnatr : @kateplusmy8 Estimated 2010 earnings: $3.5 million for 1 friggin' year yet she cries poor & can't afford to take kids to movies or gym.

2012-05-22T09:20:15Z - Reply - View Tweet
webskyper : Q2 2010 Earnings Call http://t.co/gEUZpuxQ #Conference #Calling

2012-05-17T11:04:26Z - Reply - View Tweet

Health-Care Overhaul and Industry Outlook: Cephalon
The drug maker expects Medicaid drug discounts to add between $7 million and $11 million in expenses this year and next, with additional reform-related expenses in 2011. ..
Health-Care Overhaul and Industry Outlook: Bristol–Myers
Bristol-Myers Squibb didn’t weigh in on what health-care overhaul legislation might mean for its 2011 outlook. ..
Health-Care Overhaul and Industry Outlook: Pfizer and Merck
Starting in 2014, the provisions of health-care overhaul legislation that will expand coverage to the previously uninsured will have a more positive effect on pharma companies. ..
Health-Care Overhaul and Industry Outlook: Allergan Little Affected
The legislative changes being implemented this year have a generally negative impact on pharma and biotech companies. ..
Health-Care Overhaul and Pharma Outlook: A Scorecard
Abbott is the latest drug maker to reduce its outlook because of health-care overhaul elements such as immediate increases in Medicaid discounts. Here’s the Dow Jones Newswires story. As earnings season continues, we’ll track what pharma companies are saying about the near-term impact of legislation on its sales and earnings ..
Health-Care Overhaul and Drugmaker Outlook: Amgen
Biotech Amgen yesterday became the latest drug company to reduce its outlook because of health-care overhaul elements such as immediate increases in Medicaid discounts. As earnings season continues, we’ll track what pharma and biotech companies are saying about the near-term impact of legislation on its sales and earnings ..

Orshe